Ovid Therapeutics Inc.
OVID
$1.19
-$0.03-2.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.34% | 50.72% | 49.50% | 33.02% | 39.58% |
| Total Depreciation and Amortization | -0.18% | 10.55% | 7.92% | -31.68% | -49.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 108.99% | -2,109.97% | -932.02% | -610.02% | -584.64% |
| Change in Net Operating Assets | -183.92% | -68.67% | -106.29% | 426.59% | 264.35% |
| Cash from Operations | 24.26% | 1.60% | -22.23% | -34.41% | -15.84% |
| Capital Expenditure | 75.00% | -15.56% | -77.50% | 57.79% | 54.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 295.80% | 414.54% | 2,251.32% | -136.15% | -144.66% |
| Cash from Investing | 295.00% | 413.01% | 2,215.23% | -136.43% | -144.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.94% | -41.52% | 16.26% | 30.48% | 133.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.83% | -98.67% | -97.96% | 6,587.39% | 9,659.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -133.33% | -100.00% | -100.00% | -- |
| Net Change in Cash | 96.95% | 70.15% | 95.85% | -5,067.88% | -3,426.62% |